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Background: Herpes simplex encephalitis is associated with substantial morbidity and mortality and may be related
to timely diagnosis and treatment. While awaiting the results of testing, hospitalization and empiric treatment with
acyclovir is recommended, though the direct and indirect costs associated with this management are substantial.
We sought to examine children hospitalized for possible herpes simplex encephalitis, following clinical and
laboratory assessment in the emergency department, and empiric treatment with acyclovir, in order to describe the
proportion receiving a complete course of treatment; and to identify the clinical variables which are associated with
receiving a complete course, as compared with an incomplete course of acyclovir.
Methods: Hospitalized children prescribed acyclovir were included in this case control study. Clinical, laboratory
and diagnostic variables were abstracted for children prescribed a complete (≥ 14 days) or an incomplete course
(<14 days) of acyclovir. Odds ratios and 95% confidence intervals were calculated.
Results: 289 children met eligibility criteria, 30 (10%) received a complete course and 259 (90%) received an
incomplete course. A history of mucocutaneous herpes simplex virus infection (p < 0.01), Glasgow Coma Scale ≤ 13
(p = 0.02), focal neurologic findings (p = 0.001) and elevated cerebrospinal fluid white blood cell count (p = 0.05)
were associated with a complete course of acyclovir.
Conclusions: Many children did not complete a full course of therapy. Unnecessary testing and treatment is
burdensome to families and the health care system. Possible predictive variables include abnormal Glascow Coma
Scale, focal neurologic findings and cerebrospinal fluid pleocytosis.
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Prospective studies have shown that herpes simplex
virus (HSV) accounts for approximately 5% of all cases
of acute encephalitis in children [1,2]. Morbidity and
mortality for herpes simplex encephalitis (HSE) are sig-
nificant and may be related to timely diagnosis and
treatment [1,3]. Although HSV cerebrospinal fluid poly-
merase chain reaction (CSF PCR) is considered the test
of choice for HSE, it has been shown that the sensitivity
in children is lower than in adults, and that a single
negative test may later become positive [1,4,5]. Mortality
rates for untreated HSE approximate 70% with* Correspondence: patricia.parkin@sickkids.ca
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reproduction in any medium, provided the orsignificant cognitive impairment in those that survive
[6]. Therefore, while awaiting the results of testing,
hospitalization and empiric treatment with acyclovir is
recommended, along with additional investigations such
as electroencephalogram (EEG) and neuro-imaging [1,6].
A body of literature has emerged regarding testing for
HSV in neonates and young infants less than 3 months
of age in Emergency Department (ED) settings [7-11].
These authors have suggested that both the direct and
indirect costs of testing are substantial, arguing for the
development of a clinical prediction rule to identify
low-risk infants [11]. Similar challenges exist in deci-
sion making regarding testing and treatment of older
children, beyond the neonatal period, presenting with
features of a possible central nervous system (CNS) in-
fection. Furthermore, while ED physicians may make
initial decisions regarding which children merit lumbard. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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treatment, hospital physicians must determine dur-
ation of acyclovir treatment, need for subspecialty
consultation and additional investigations, and time of
hospital discharge.
The objective of this study was to examine children
hospitalized for possible HSE, following clinical and la-
boratory assessment in the ED, and initiation of empiric
treatment with acyclovir, in order to describe the pro-
portion receiving a complete course of treatment; and to
identify the clinical variables, obtained within the first
12 hours of assessment, which are associated with the
children receiving a complete course of acyclovir, as
compared with an incomplete course of acyclovir.
Methods
This case-control study was conducted on patients ad-
mitted to the Pediatric Medicine Inpatient Unit (PMIU)
at the Hospital for Sick Children, Toronto, Canada. In
our institution, children are initially assessed in the
Pediatric Emergency Department, where initial clinical
assessment, investigations and empiric therapy is often
initiated. Children with suspected HSE who are not im-
munocompromised and do not require intensive care
are admitted to the PMIU and attended by Pediatric
Hospitalists. This unit has approximately 4000 admis-
sions per year [12]. The attending Hospitalists are the
primary decision makers regarding ongoing therapy.
Since 1994, all children who fulfill previously described
stringent criteria (but not all children for whom HSE is
initially considered) have been prospectively enrolled in
an encephalitis registry [1]. Patients in the registry were
considered to have encephalitis if they had depressed or
altered level of consciousness persisting for >24 hours,
plus ≥ 2 of the following: fever (>38°C), seizure, focal
central nervous system findings, CSF pleocytosis (>5 ×
106 cells per L), electroencephalogram (EEG) abnormal-
ities, or diagnostic imaging abnormalities. EEG abnor-
malities included generalized background slowing and
periodic lateralizing epileptiform discharges (PLEDS)
and neuroimaging abnormalities included localized
edema, mass effect, high/low-density lesions, or infarc-
tion and hemorrhage, with localization to the limbic,
parietal, frontal, occipital lobes or thalami [1].
For the current study, children were eligible for inclu-
sion if they had been assessed in our ED, underwent a
lumbar puncture, CSF was sent for HSV PCR, empiric
acyclovir had been initiated (at least one dose received),
and the child was admitted to the PMIU and attended
by a Pediatric Hospitalist. This sequence of assessment,
testing and treatment was considered a proxy for a phy-
sician’s decision to consider the diagnosis of HSE. The
study period was January 2000 to April 2008 (January
2000 was selected since this was the date from whichelectronic charts were available for review). Exclusion
criteria were direct admission to the Pediatric Intensive
Care Unit (PICU) or a subspecialty inpatient unit, age
less than 30 days, immunocompromised state, primary
respiratory infection with no neurologic presentation,
suspected or confirmed HSV disease restricted to muco-
cutaneous sites or if varicella zoster virus was the cause
of the child’s illness (see Figure 1). At our institution,
there is a high threshold for admitting patients with sus-
pected encephalitis to the PICU, representing children
with more severe neurologic symptoms and a higher
pre-test probability of CNS infection, leading to different
physician approaches to clinical decision making.
The primary source for identifying eligible children
was the hospital pharmacy database through which we
identified all children receiving at least one dose of
acyclovir. The encephalitis registry database was used
as a secondary source to cross-check identification of
children with confirmed HSE who received intravenous
acyclovir. One child was identified from the encepha-
litis database that was not noted in the pharmacy
database.
Study definitions
Cases were defined as children prescribed 14 days or
more of intravenous acyclovir and controls as children
prescribed a shorter duration. At our institution, a
complete course of acyclovir was considered 14 days
prior to 1999 and 21 days after 1999 [1]. While physi-
cian’s written discharge diagnosis is prone to error and
variation in documentation, the prescription of a
complete course of acyclovir is an explicit measure of
the attending physician’s decision making.
Based on findings of the prospective study of children
with HSE [1], the study team generated a number of
potential predictors of acute CNS infection, including
history, symptoms and physical examination findings
at initial assessment, and initial laboratory investiga-
tions. A normal CSF WBC count was defined as 0–5
cells ×106/L; adjustment for a bloody tap was per-
formed according to the following formula: true
WBC in CSF = actual WBC count in CSF – {(WBC
in blood X RBC in CSF)/RBC in blood} [13,14]. Diag-
nostic investigations completed beyond the first
12 hours of initial assessment (EEG, CT, MRI, CSF
PCR) were included in the secondary analysis. DMK
reviewed the pharmacy database and encephalitis regis-
try to determine eligibility. Data were abstracted from
hospital records by DMK and MY using a standardized
data collection form.
Standard statistical methods were employed. Group
comparisons were done using the t-test for continuous
variables and chi-square for categorical variables; odds
ratios and 95% confidence intervals were calculated.
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Figure 1 Selection process for study inclusion.
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A total of 3063 patients were prescribed at least one
dose of intravenous acyclovir between January 2000 and
April 2008. 2774 were excluded for the following
reasons: (a) admission to an inpatient unit other
than the PMIU (oncology unit n = 1010; PICU n = 644;
NICU n = 242; surgical or transplant unit n = 222);
(b) suppressed immune system (n = 352); (c) mucocuta-
neous lesions consistent with varicella zoster virus in-
fection, HSV stomatitis or eczema herpeticum (n = 137);
(d) primary respiratory illness consistent with pneumo-
nia or pneumonitis (n = 3); (e) age <30 days (n = 87),
(f ) repeat or incorrect entries (n = 77) (see Figure 1).
The remaining 289 subjects were included in the ana-
lysis; of these, 30 (10%, 95% Confidence Interval 7-13%)
were prescribed 14 or more days of intravenous acyclo-
vir (median 20.0, IQR 5.25 days) and 259 (90%, 95%
Confidence Interval 87-93%) less than 14 days of such
therapy (median 2.0, IQR 2.0 days). All of the children
who received acyclovir had CSF HSV testing performed
(PCR or culture).
The most common presenting clinical manifestations
observed in the 289 included subjects were fever (66%),
seizures (46%) and headache (27%). Other manifestations
included altered level of consciousness (19%), meningis-
mus (16%), vomiting (10%), ataxia (9%) and personality
changes (7%). Intravenous acyclovir was initiated within
24 hours of admission in 95% of cases. Ceftriaxone,cefotaxime and vancomycin were given to 191 (66%), 48
(17%) and 95 (33%), respectively, pending CSF and blood
culture results. Anticonvulsants, predominantly benzo-
diazepines (n = 70, 24%), phenobarbital (n = 47, 16%) and
phenytoin (n = 43,15%), were used in 105 (36%).
A comparison of clinical and laboratory variables in
children prescribed an incomplete or a complete course
of acyclovir is shown in the Table 1. Patients prescribed
<14 days of acyclovir received a median of two days of
therapy. Patients prescribed ≥ 14 days of acyclovir were
likely to have a discharge diagnosis consistent with the
treating physicians’ suspicion of acute CNS infection.
Twelve of 30 patients received discharge diagnoses of
“encephalitis” or “rule out encephalitis”. Other discharge
diagnoses included: acute disseminated encephalomyeli-
tis (7/30), headache/migraine (2/30), meningitis/possible
meningitis (6/30), seizures (4/30), cerebellitis (3/30),
neurologic symptoms not yet diagnosed (1/30) and en-
cephalopathy (1/30). Some patients received greater than
one discharge diagnosis.
In the primary analysis of predictors at the time of ini-
tial assessment, a history of concurrent mucocutaneous
HSV infection in the child (p < 0.01), Glasgow Coma
Scale (a measure of decreased level of consciousness) ≤
13 (p = 0.02), focal neurologic findings (p = 0.001) and
elevated CSF WBC (p = 0.05) all differed significantly be-
tween the two groups. Variables that were not signifi-
cantly different included: history of fever, seizure, or










Age (years), median (range) 3.8 (0.01-18) 6.8 (0.07 – 16.7) 0.2
Sex (male), n (%) 152 (59) 13 (43) 0.5 (0.2 – 1.2) 0.1
History of fever, n (%) 171 (66) 19 (63) 0.9 (0.4-2.0) 0.8
History of seizure, n (%) 120 (46) 13 (43) 0.9 (0.4-1.9) 0.8
History of headache, n (%) 70 (27) 9 (30) 1.1 (0.5-2.6) 0.7
History of mucocutaneous HSV, n (%) 3 (0.8) 3 (10) 14.3 (2.3 – 89) <0.01*
Clinical variables, physical examination
Fever (≥ 38 C), n (%) 95 (37) 12 (40) 1.2 (0.5 – 2.5) 0.7
Glasgow Coma Scale ≤ 13, n (%) 80 (32) 16 (53) 2.5 (1.2-5.3) 0.02*
Focal neurologic findings, n (%) 30 (12) 11 (37) 4.4 (1.9-10.2) 0.001*
Seizure in ED, n (%) 38 (15) 5 (17) 1.2 (0.4 – 3.2) 0.7
Initial laboratory measures
WBC, mean (±SD) 13.1 (7.9) 12.7 (6.3) 0.8
CSF corrected WBC, median (range) 4 (0-838) 16 (0-650) 0.05*
CSF protein, median (range) 0.3 (0.1-830) 0.4 (0.1-44) 0.8
Diagnostic investigations
CT head abnormal, n/N completed (%) 33/194 (17) 7/17 (41) 3.4 (1.2-9.6) 0.03*
MRI head abnormal, n/N completed (%) 46/98 (47) 17/24 (71) 2.7 (1.0-7.2) 0.04*
EEG abnormal, n/N completed (%) 52/128 (41) 16/22 (73) 3.9 (1.4-10.6) 0.005*
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ation; serum WBC and CSF protein (see Table 1). Add-
itional variables not shown in the Table 1 that were
not found to be significantly different between the
two groups included vomiting, dizziness, behavior
changes, dysarthria, ataxia, hallucinations, peripheral
band count, CSF glucose, liver function tests and cre-
atinine. No children developed renal failure (>50% rise
in baseline creatinine).
Some, but not all, children had additional diagnostic
investigations which were not considered part of the
child’s initial assessment and were included in the sec-
ondary analysis (see Table 1). Compared with children
prescribed an incomplete course of acyclovir, children
with a complete course of acyclovir more frequently had
an abnormal CT head scan (p = 0.03), MRI brain scan
(p = 0.04), or EEG (p = 0.005) within the first 48 hours
of presentation.
In four of the 289 included patients, HSV-1 was
detected in the CSF by PCR. Two had decreased level of
consciousness (GCS ≤ 13) and focal neurologic deficits.
None had significantly abnormal CSF counts, protein or
glucose levels. The EEG was abnormal in 2 of 3 patients
tested. Two patients had CT scans of the head, one of
which was abnormal. MRI of the brain was abnormal inthe 3 patients assessed. All four were prescribed ≥14 days
of acyclovir treatment, though one patient received the
first acyclovir dose after 24 hours of admission.
Discussion
We have demonstrated that at our institution 90% of
children who received a lumbar puncture, CSF testing
for HSV PCR, initiation of empiric intravenous acyclovir
and admission to hospital did not complete a full course
of acyclovir. These children were hospitalized with a me-
dian duration of therapy of two days and more than 70%
received additional investigations including EEG and
neuro-imaging. Thus, for every one child for whom this
sequence of testing and treatment was necessary, nine
children received the same sequence unnecessarily.
This study was undertaken from the perspective of the
hospital physician who is responsible for making deci-
sions regarding the duration of acyclovir treatment, need
for subspecialty consultation and additional investiga-
tions, and time of hospital discharge. Hospital physicians
recognize that testing, treatment and hospitalization are
burdensome to children and families, and to the health
care system; further, hospital physicians are aware that
acyclovir is nephrotoxic, may lead to acute renal failure
and that concurrent use of antibiotics (including
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curred in the majority of our study patients, may aug-
ment the nephrotoxic effects of acyclovir [15-19].
Although HSE is associated with high mortality and
morbidity, we believe that the current rate of unneces-
sary testing and treatment should be considered exces-
sive, and this should motivate further research.
The prospective study by Elbers and colleagues
demonstrated that HSE is a rare condition, even in a re-
ferral center, with 16 confirmed cases over 12 years, ap-
proximately 1–2 cases per year [1]. These investigators
identified the following clinical variables and their fre-
quency in the 16 confirmed cases: encephalopathy
(defined as depressed or altered level of consciousness
persisting for > 24 hours) in 100% (this was a require-
ment for enrollment in their registry); fever (100%); focal
seizures at presentation (69%); history of, or exposure to
HSV (50%); hemiparesis (31%); dysphasia (13%). Initial
laboratory variables were as follows: CSF pleocytosis
(>5 × 106 cells per L) (94%); elevated CSF protein
(50%); CSF red blood cells of 50 to 100 × 106 per L
(19%). These initial clinical and laboratory variables
should inform clinicians however, without a control
group (for example, children undergoing a lumbar
puncture who do not have HSE), the strength of these
variables to predict HSE remains unknown.
Considering the findings from the prospective study
and our case–control study together suggests two inter-
pretations which warrant further investigation. First,
current practice is not consistent with what is currently
known about the clinical and laboratory findings in chil-
dren with HSE. For example, from the prospective study
all children with confirmed HSE had altered level of
consciousness and fever and almost all had CSF pleocy-
tosis; in contrast in our case–control study less than
40% had these features. Second, while awaiting a con-
trolled prospective study of children with and without
HSE, there are several variables that were associated
with HSE in both the uncontrolled prospective study
and our retrospective case–control study. These may
guide clinicians in the judicious use of CSF HSV PCR
testing and initiation of empiric acyclovir.
An important body of literature has emerged regarding
testing for HSV in neonates and young infants less than
3 months of age in Emergency Department (ED) settings
[9-11]. This research has been stimulated by the lack of
consensus regarding which infants merit testing and
concerns regarding over-testing. These studies have con-
cluded that factors currently used by physicians in the
decision to order CSF HSV PCR testing do not best re-
flect the likelihood of HSV infection as described by the
literature [9]; there is considerable practice variation
amongst Emergency Department physicians [10]; and
infants undergoing testing have a significantly longerlength of hospital stay and higher hospital charges
[11]. The results of our case–control study of all-aged
children in an Inpatient Pediatric setting have identified
remarkably similar findings. We have further high-
lighted the downstream impact of testing upon hospital
length of stay, treatment with intravenous acyclovir,
ordering of advanced investigations and requesting of
subspecialty consultation.
Shah and colleagues have suggested that both the dir-
ect and indirect costs of testing are substantial, arguing
for the development of a clinical prediction rule to iden-
tify low-risk infants [11]. We strongly concur that deriv-
ation of a clinical prediction rule is warranted, and
suggest that such a rule include all-aged children, per-
haps with stratification in two age groups (< 3 months;
> 3 months). Clinical prediction rules aim to reduce
uncertainty, improve accuracy in medical decision
making and minimize the use of potentially harmful
diagnostic tests.
They have been defined as clinical decision-making
tools that quantify the relative importance of three or
more variables from history, physical examination, or
simple tests to provide the probability of an outcome
or suggest a single diagnostic or therapeutic course of
action for an individual patient [20,21].
Similar to the studies in infants < 3 months [9-11], the
primary limitation of this study was its retrospective na-
ture. The use of retrospective data is limited by the ac-
curacy and completeness of the original data collection.
Our study included only children admitted to the PMIU,
and is therefore not generalizable to children with more
severe disease, such as those admitted to intensive care
units. Clinical decision making varies by practice setting
where there are differences in pre-test probabilities and
variations in practice. While it is possible that some chil-
dren were discharged from our institution after cessation
of acyclovir therapy only to be diagnosed with HSE at
another institution, this is unlikely. Our institution is the
only regional quaternary children’s hospital, and other
hospitals commonly refer children with chronic and life
threatening illnesses such as encephalitis to our center.
Conclusion
Our study demonstrates that a large proportion of chil-
dren who receive a lumbar puncture, CSF testing for
HSV PCR and initiation of empiric intravenous acyclovir
do not complete a full course of such therapy. As shown
for neonates and young infants, there is significant phys-
ician practice variation; current practice does not reflect
what is currently known; and over-use of testing and
treatment is burdensome to children, families and the
health care system. Derivation of a clinical prediction
rule identifying all-aged children at low risk for HSE is
warranted. Variables which may be predictive include
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and CSF pleocytosis. Future studies are recommended to
determine if these variables remain predictive in other
populations of infants at risk for HSE.
Abbreviations
HSE: Herpes simplex encephalitis; OR: Odds ratio; CI: Confidence interval;
PCR: Polymerase chain reaction; HSV: Herpes simpex virus; LOC: Level of
consciousness; MRI: Magnetic resonance imaging; FLAIR: Fluid attenuation
inversion recovery; CSF: Cerebral spinal fluid; PMIU: Pediatric medicine
inpatient unit; PICU: Pediatric intensive care unit; NICU: Neonatal intensive
care unit; CT: Computed tomography; CBC: Complete blood count;
EEG: Electroencephalogram; GCS: Glasgow Coma Scale; IQR: Interquartile
range; LP: Lumbar puncture.
Competing interests
The authors have no competing interests to disclose.
Authors’ contributions
PCP conceived of the study. DMK and PCP designed the study. DMK and MY
performed the chart review. DMK, MM, AB and PCP analyzed the data. DMK
drafted the manuscript and all authors read and approved of the manuscript.
Acknowledgements
The Pediatric Outcomes Research Team (PORT) is supported by a grant from
the Hospital for Sick Children Foundation, Toronto, Canada.
Author details
1Divisions of Pediatric Medicine and the Pediatric Outcomes Research Team
(PORT), University of Toronto, Faculty of Medicine, Toronto, ON, Canada.
2Division of Infectious Diseases, University of Toronto, Faculty of Medicine,
Toronto, ON, Canada. 3Departments of Pediatrics, University of Toronto,
Faculty of Medicine, Toronto, ON, Canada. 4Health Policy, Management and
Evaluation, University of Toronto, Faculty of Medicine, Toronto, ON, Canada.
5Child Health Evaluative Sciences, Hospital for Sick Children Research
Institute, Toronto, ON, Canada. 6The Hospital for Sick Children, 555 University
Ave, Toronto, ON M5G 1X8, Canada.
Received: 4 September 2012 Accepted: 13 December 2012
Published: 17 December 2012
References
1. Elbers JM, Bitnun A, Richardson SE, Ford-Jones EL, Tellier R, Wald RM,
Petric M, Kolski H, Heurter H, MacGregor D: A 12-year prospective study of
childhood herpes simplex encephalitis: is there a broader spectrum of
disease? Pediatrics 2007, 119:e399–e407.
2. Koskiniemi M, Rautonen J, Lehtokoski-Lehtiniemi E, Vaheri A: Epidemiology
of encephalitis in children: a 20-year survey. Ann Neurol 1991, 29:492–497.
3. Lahat E, Barr J, Barkai G, Paret G, Brand N, Barzilai A: Long term
neurological outcome of herpes encephalitis. Arch Dis Child 1999,
80:69–71.
4. Troendle-Atkins J, Demmler GJ, Buffone GJ: Rapid diagnosis of herpes
simplex virus encephalitis by using the polymerase chain reaction.
J Pediatr 1993, 123:376–380.
5. Weil AA, Glaser CA, Amad Z, Forghani B: Patients with suspected herpes
simplex encephalitis: rethinking an initial negative polymerase chain
reaction result. Clin Infect Dis 2002, 34:1154–1157.
6. Steiner I, Budka H, Chaudhuri A, Koskiniemi M, Sainio K, Salonen O, Kennedy
PG: Viral meningoencephalitis: a review of diagnostic methods and
guidelines for management. Eur J Neurol 2010, 17:999–e57.
7. Kneen R, Michael BD, Menson E, Mehta B, Easton A, Hemingway C, Klapper
PE, Vincent A, Lim M, Carrol E, et al: Management of suspected viral
encephalitis in children - Association of British Neurologists and British
Paediatric Allergy, Immunology and Infection Group national guidelines.
J Infect 2012, 64:449–477.
8. Kelly C, Sohal A, Michael BD, Riordan A, Solomon T, Kneen R: Suboptimal
management of central nervous system infections in children: a multi-
centre retrospective study. BMC Pediatr 2012, 12:145.9. Cohen DM, Lorch SA, King RL, Hodinka RL, Cohn KA, Shah SS: Factors
influencing the decision to test young infants for herpes simplex virus
infection. Pediatr Infect Dis J 2007, 26:1156–1158.
10. Davis KL, Shah SS, Frank G, Eppes SC: Why are young infants tested for
herpes simplex virus? Pediatr Emerg Care 2008, 24:673–678.
11. Shah SS, Volk J, Mohamad Z, Hodinka RL, Zorc JJ: Herpes simplex virus
testing and hospital length of stay in neonates and young infants.
J Pediatr 2010, 156:738–743.
12. Dwight P, MacArthur C, Friedman JN, Parkin PC: Evaluation of a staff-only
hospitalist system in a tertiary care, academic children's hospital.
Pediatrics 2004, 114:1545–1549.
13. Bonadio WA: The cerebrospinal fluid: physiologic aspects and alterations
associated with bacterial meningitis. Pediatr Infect Dis J 1992, 11:423–431.
14. Tunkel A: Approach to the patient with central nervous system infection.
In Principles and Practice of Infectious Diseaseseds (sixth edition). Edited by
Mandell GL, BJDR. Philadelphia: Churchill Livingston; 2005:1079–1083.
15. Eck P, Silver SM, Clark EC: Acute renal failure and coma after a high dose
of oral acyclovir. N Engl J Med 1991, 325:1178–1179.
16. Sawyer MH, Webb DE, Balow JE, Straus SE: Acyclovir-induced renal failure.
Clinical course and histology. Am J Med 1988, 84:1067–1071.
17. Schreiber R, Wolpin J, Koren G: Determinants of aciclovir-induced
nephrotoxicity in children. Paediatr Drugs 2008, 10:135–139.
18. Izzedine H, Launay-Vacher V, Deray G: Antiretroviral drugs and the kidney:
further precisions. Kidney Int 2005, 68:409.
19. Vomiero G, Carpenter B, Robb I, Filler G: Combination of ceftriaxone and
acyclovir - an underestimated nephrotoxic potential? Pediatr Nephrol
2002, 17:633–637.
20. Laupacis A, Sekar N, Stiell IG: Clinical prediction rules. A review and
suggested modifications of methodological standards. JAMA 1997,
277:488–494.
21. McGinn TG, Guyatt GH, Wyer PC, Naylor CD, Stiell IG, Richardson WS: Users’
guides to the medical literature: XXII: how to use articles about clinical
decision rules. Evidence-Based Medicine Working Group. JAMA 2000,
284:79–84.
doi:10.1186/1824-7288-38-72
Cite this article as: Kulik et al.: Should a hospitalized child receive
empiric treatment with acyclovir?. Italian Journal of Pediatrics 2012 38:72.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
